Setting: Bispebjerg Hospital, Department of Pulmonary Medicine, tuberc
ulosis referral center for the Municipality of Copenhagen. Objective:
To evaluate routine procedure for the management of liver injury durin
g antituberculosis treatment. Design: From 1983-1993, 765 patients for
whom we could trace 752 files (98%) were treated at our ward with sta
ndard Danish treatment for tuberculosis. From 1983-1986 they received
a three-drug (9-month) regimen and from 1986-1993 a four-drug (6-month
) regimen consisting of isoniazid, rifampicin, ethambutol + pyrazinami
de. Data from a retrospective chart review. Results: An increase in as
partate aminotransferase (AST) of more than twice the upper limit of n
ormal (ULN) was recorded in 127 patients (16%). 66 had elevated AST be
fore treatment; most of these were men with a daily alcohol consumptio
n in excess of 60 g. In the remaining 61 patients (8%) AST increased d
uring antituberculosis treatment. 30 of these patients were excessive
alcohol consumers, and seven had alcoholic liver cirrhosis. Despite an
increase in AST of median 6 x ULN (range 2-25 x ULN), it was possible
to continue treatment in 31 (15 excessive alcohol consumers) or reint
roduce it fully in 14 (12 excessive alcohol consumers). Only 16 patien
ts (2%), including 11 women with no daily alcohol consumption, needed
a modified regimen. These patients were older (P < 0.05), seven were j
aundiced, and one had alcoholic liver cirrhosis. Hepatotoxicity was co
nfirmed by challenge with pyrazinamide (n = 7), isoniazid (n = 6) and
combined isoniazid/rifampicin (n = 1). No deaths were caused by hepato
toxicity. Conclusion: In spite of an increase in AST levels to approxi
mately 6 x ULN during antituberculosis treatment, the drugs can be con
tinued or reintroduced in full in most cases. Risk factors of hepatoto
xicity included old age, female sex and extensive tuberculosis, and no
t alcohol consumption. Overall, hepatotoxicity during antituberculosis
treatment can be monitored and managed easily.